Lilly’s John Lechleiter elected as PhRMA Board chairman
pharmafile | April 17, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene, John Lechleiter, Pfizer, Sanofi, lilly
John Lechleiter, chairman, president and chief executive of Lilly has been elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Also elected were Celgene Corporation president, chief executive, and chairman Robert Hugin as chairman-elect of the PhRMA Board of directors, and Ian Read, president and chief executive of Pfizer, as board treasurer.
Dr Lechleiter succeeds Christopher Viehbacher, chief executive of Sanofi, as PhRMA’s chairman.
“Chris has been indispensable to PhRMA on many fronts, providing invaluable leadership as the industry navigates the evolving policy and regulatory landscapes essential to continued innovation while always putting patients first,” said PhRMA president and chief executive John Castellani.
“As Dr Lechleiter assumes the chairman role, we can all feel comfort knowing that the patient-centered approaches we utilise in all our advocacy efforts will continue to be central to our mission of advancing innovation in the U.S and worldwide. It is an honor to work closely with these visionary, passionate leaders of our sector.”
Lechleiter has served as chairman, president, and chief executive of Lilly since 2008. He became president and chief operating officer of Lilly in 2005, when he joined the company’s board of directors.
His career at Lilly began in 1979 as a senior organic chemist in process research and development – a department he later led in 1982. He was named executive vice president for pharmaceutical products and corporate development in 2001. In 2004, he became Lilly’s executive vice president for pharmaceutical operations.
Lechleiter said: “PhRMA member companies play an incredibly important role in the delivery of high-quality, cost-effective health care for our citizens. Continued progress against diseases like Alzheimer’s disease, cancer, and diabetes requires policies that enable medical innovation to thrive. I look forward to the opportunity to advance these important conversations at an industry level.”
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
